{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'perform full physical and neurological examinations (including height and weight;', 'note: weight must be measured with shoes and outerwear off)', 'perform 12-lead ECG (Note: ECG will be performed after at least 5 minutes rest in a', 'supine or semi-supine position.)', 'perform clinical laboratory tests, including chemical, hematological, and urine', 'analyses', 'perform UDS', 'perform serum pregnancy (B-HCG) test (only in females who are postmenarchal or', '>12 years of age)', 'administer the following questionnaires (Note: For C-SSRS,', 'and C&A-GTS-QOL, children 13 years of age and under may be', 'interviewed separately or jointly with the caregiver/adult as appropriate or defined by', 'the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should', 'be encouraged to add relevant information. The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', \"- C-SSRS (children's SLV)\", '- YGTSS (Input from the caregiver/adult is required.)', '- TS-CGI', '-', 'TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', '-', '- C&A-GTS-QOL', 'assess drug accountability and compliance', 'collect used and unused IMP blister packs', 'inquire about adverse events', 'review concomitant medications', '3.13.4.', 'Procedures After IMP Treatment', 'Patients who participate in the study in compliance with the protocol for at least 12 weeks of', 'double-blind treatment will be considered to have completed the study. See Section 12.4 for the', 'definition of the end of the study.', '62']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'All patients will discontinue IMP at the week 12 visit and will return 1 week later for evaluation', 'of safety and tic reduction (week 13 visit; see Section 3.13.4.1). Patients who complete the study', 'may be eligible to begin participation in an open-label safety extension study TV50717-CNS-', '30047. Patients not participating in Study TV50717-CNS-30047 will have a follow-up telephone', 'contact for safety evaluation 1 week after the end of the washout period (2 weeks after their last', 'dose of IMP [week 14 visit]; see Section 3.13.4.2).', 'For patients who withdraw prematurely an early termination visit (see Section 3.13.3.2.2 for', 'applicable procedures) should be conducted as soon as possible after the last dose of IMP. All', 'patients who discontinue early will have a follow-up telephone contact for safety evaluation', '2 weeks after their last dose of IMP; evaluations will be as described for week 14', '(Section 3.13.4.2). Additional details for patients who withdraw prematurely from the study are', 'described in Section 4.4.', 'As appropriate, patients should be treated with standard of care following termination of the', 'study.', 'Data from any efficacy evaluations performed after the specified time will not be collected on', 'the CRF; in the event, however, that such data are collected, these data will not be analyzed.', 'Patients with ongoing adverse events or clinically significant abnormal laboratory test results (as', 'interpreted by the investigator) will be monitored as described in Section 4.4 and Section 7.1.2.', '3.13.4.1. Week 13', 'The following procedures/assessments will be performed at the in-person clinic visit at week 13:', 'conduct clinic visit', 'measure vital signs (pulse, BP, body temperature, and respiratory rate)', 'measure weight (Note: weight must be measured with shoes and outerwear off)', 'for patients with clinically significant laboratory abnormalities at week 12, repeat', 'those laboratory evaluations at this visit', 'administer the following questionnaires (The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', '-', \"C-SSRS (children's SLV; Note: Children 13 years of age and under may be\", 'interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult', 'involvement is strongly encouraged. Questions should be directed to the child,', 'but the caregiver/adult should be encouraged to add relevant information.)', '- YGTSS (Note: Perform assessment of \"Severity Ratings\" of the questionnaire.', 'Inventory portions, ie, \"Motor Tic Symptom Checklist\" and \"Phonic Tic', '63']\n\n###\n\n", "completion": "END"}